Multi-Center, Double-Blind Clinical Study Validates DefenAge® as a Best-in-Class Anti-Aging Solution, Naturally Turning Back the Clock
Progenitor Biologics®, LLC, the manufacturer and distributor of the cutting-edge anti-aging skin care products, DefenAge ® Skincare, is proud to announce the results of a new comprehensive clinical study of the line’s breakthrough ingredient Age-Repair Defensins ®. The defensin-based three-step system “globally improves the visual appearance of aging skin without irritation, dryness, or inflammation,” concludes the peer-review article published by the Journal of Drugs in Dermatology (JDD). Target-specific Age-Repair Defensins represents the latest generation of anti-aging technology and is the FIRST of a kind.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180402005989/en/
DefenAge's core regimen, 12 weeks. Taub A, Bucay V, Keller G et al. J Drugs Dermatol. 2018 Apr;17(4):426-441. (Graphic: Business Wire)
“The defensin skin care regimen resulted in statistically significant improvements in ALL five parameters in patients simultaneously including decreased visible fine and coarse wrinkles, pore size and visible pigmentation. Study participants also demonstrated improvement in skin’s oiliness, evenness, hydration and a number of other crucial skin’s qualities” shares the study’s principal investigator and correspondence author, Amy Forman Taub, MD. “DefenAge results in profound improvements in the visible health and beauty of the skin that are readily apparent to even the untrained eye.”
“The results showed that the defensin-containing trio of products offer most of the advantages of time-honored retinols as well as newer but widely used growth-factor containing cosmeceuticals, without irritation or inflammation, sun-sensitivity, or concerns about neoplasia of the treated skin,” adds the study’s co-investigator, Vivian Bucay, MD. “The observed clinical results put DefenAge Skincare into the best-in-class category without doubt, this is a landmark product.”
The earlier-published pre-clinical research shows that defensins activate dormant preserve of “fresh” cells in the body, LGR6-positive stem cells. “After activation, LGR6-positive stem cells physically migrate into the basal layer of the skin and create a new epidermis, and eventually, new, younger-acting skin,” explains the study’s co-investigator, Gregory Keller, MD. “The defensin-based anti-aging technology is an authentic paradigm shift that I see only once per decade.”
“DefenAge made an initial soft launch in the summer of 2015,” comments Progenitor Biologics’ CEO, Nikolay Turovets, PhD. “Today, more than 300 US-based aesthetic physicians and medi-spas offer DefenAge. Since the launch, DefenAge’s annual growth exceeded 100 percent three years in a row, having sales in 2017 that exceeded $2.4M. Now having such solid clinical proof of the product’s performance, we will continue our expansion in the aesthetic market and deliver the best technologies to consumers.”
The study was conducted by Amy Forman Taub, MD, Vivian Bucay, MD, Gregory Keller, MD, Jay Williams, PhD, and Darius Mehregan, MD. A participant- and investigator -blinded, placebo-controlled, multi-center trial was performed in outpatient settings on forty-four female subjects, 41-71 years old, skin types I-V. The evaluation was performed at baseline, 6 and 12 weeks. The DefenAge 3-step system (trade name: Clinical Power Trio) includes: 2-Minute Reveal Masque, 24/7 Barrier Balance Cream and 8-in-1 BioSerum. The peer-review article is entitled: ”Multi-center, double-blind, vehicle-controlled clinical trial of an alpha and beta defensin-containing anti-aging skin care regimen with clinical, histopathologic, immunohistochemical, photographic, and ultrasound evaluation” [Taub A, et al. J Drugs Dermatol. 2018 Apr;17(4):426-441].
Read the full-text article in the JDD April 2018 issue: http://jddonline.com/articles/dermatology/S1545961618P0426X
DefenAge ® Skincare is a technology-driven anti-aging skin care line, primarily distributed through the professional aesthetic market including dermatology and aesthetic surgery practices. The key ingredient, Age-Repair Defensins ®, features a stand-alone natural target-specific mechanism of action. The technology is patent-pending, exclusively available in DefenAge and does not belong to the growth factor category. The Clinical Power Trio is clinical study tested, DefenAge’s core skin care regimen that addresses visible signs of skin aging on a global scale. DefenAge products do not contain: animal- or human- originated ingredients, parabens, formaldehyde-releasing preservatives, sulfates, mineral oils, colorants, phthalates or BPA.
The products are available at www.DefenAge.com .
For more information, please visit www.DefenAge.com
or connect with the company on
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
PSE: APM Forum 2018 Focus on Digitalisation for the Process Industries20.4.2018 15:13 | Pressemelding
At the 2018 Advanced Process Modelling (APM) Forum this week, process industry organisations presented on digital design and operations applications ranging from accelerating development of the next generation of pharmaceuticals to realising millions of dollars per year in increased profit for large process plants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180420005517/en/ Ben Weinstein, head of R&D Product and Process Systems Modeling at Procter & Gamble, delivers the keynote speech on how digital design techniques are used systematically to accelerate innovation in P&G. (Photo: Business Wire) Introducing the conference, Prof. Costas Pantelides, MD of conference host Process Systems Enterprise (PSE), described the current wave of digitalisation as the culmination of many years of advanced modelling and IT development. “This is a time of extraordinary opportunities for the process industries” he said. Keynote speaker Ma
Aperta Provides Electronic Funds Transfer (EFT) in Cayman Islands20.4.2018 14:01 | Pressemelding
Once again, the Aperta Active Clearing System (ACS) has delivered the mechanism for a country to implement a world-class electronic payment processing environment to maximize a national payments system’s efficiency, effectiveness, security and control. Aperta partnered with the Cayman Islands ACH Operator (Prism Services (Cayman) Ltd.) and local commercial banks to deliver a new Electronic Funds Transfer system. The old process of banks swapping files in a wide-variety of standards and settling bilaterally has been replaced with a common system and standards, employing international-standard secure file transfer protocol, allowing participants to monitor real time net settlement and collateral positions via a secure portal. The Cayman Islands Automated Clearinghouse (CIACH) links all six of the country’s banks and provides the central clearing and settlement mechanism for banks to exchange direct debit and direct credit transactions seamlessly across the country. It is functionally NAC
FII Tech Growth Invests in SECO20.4.2018 13:39 | Pressemelding
FII Tech Growth, a fund managed by Fondo Italiano d’Investimento SGR, announces today its second investment in SECO SpA, one of the European leaders in the embedded electronics market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180420005413/en/ (Photo: SECO) SECO, headquartered in Arezzo, Tuscany, with subsidiaries in the U.S.A., Germany and Taiwan, was founded in 1979 by entrepreneurs Daniele Conti and Luciano Secciani. The company designs and manufactures micro-computers and integrated systems for industrial applications. With more than 250 employees, SECO supports customers with a worldwide presence such as Cimbali, Esaote, Technogym and Vimar, and generated revenue in excess of Euro 50 million in 2017. The ability to offer innovative solutions by using cutting-edge technologies has allowed SECO to grow steadily over time. The company developed a network of collaborations with universities and research centres La Sapi
Schlumberger Announces First-Quarter 2018 Results20.4.2018 11:05 | Pressemelding
Schlumberger Limited (NYSE:SLB) today reported results for the first quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Mar. 31, 2018 Dec. 31, 2017 Mar. 31, 2017 Sequential Year-on-year Revenue $7,829 $8,179 $6,894 -4% 14% Pretax operating income $974 $1,155 $757 -16% 29% Pretax operating margin 12.4% 14.1% 11.0% -169 bps 145 bps Net income (loss) - GAAP basis $525 $(2,255) $279 n/m 88% Net income, excluding charges & credits* $525 $668 $347 -21% 51% Diluted EPS (loss per share) - GAAP basis $0.38 $(1.63) $0.20 n/m 90% Diluted EPS, excluding charges & credits* $0.38 $0.48 $0.25 -21% 52% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. n/m = not meaningful Schlumberger Chairman and CEO Paal Kibsgaard commented, “As forecast, our results in the first quarter of 2018 largely reflected transitory factors, with seasonal reductions in activity in the Northern Hemisphere and planned project startup costs
Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases20.4.2018 10:30 | Pressemelding
Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced today they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases. This collaboration capitalizes on Biogen’s expertise in neuroscience research and drug development and Ionis’ leadership in RNA targeted therapies with the goal of developing a broad pipeline of investigational therapies. It builds upon a productive collaboration that produced SPINRAZA, the first and only approved treatment for patients with spinal muscular atrophy. Today, April 20, 2018, Biogen and Ionis will host company conference calls and webcasts to discuss the new collaboration. Full webcast details can be found below. Under the terms of the collaboration, Biogen will pay Ionis $1 billion in cash, which will include $625 million to purchase 11,501,153 shares of Ionis common stock at a price of $54.34 per share, at an appr
Versum Materials Celebrates the Grand Opening of Its Research and Development Facility in Hometown, PA19.4.2018 20:37 | Pressemelding
Versum Materials, Inc. (NYSE: VSM), a leading materials supplier to the semiconductor industry, announced today the grand opening of its new research and development (R&D) facility at its semiconductor materials manufacturing site in Hometown, Pennsylvania. The ribbon-cutting ceremony took place April 10, 2018. Versum employees, members of the community, local government, customers and strategic partners attended the event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180419006305/en/ Versum Materials ribbon-cutting ceremony at the company's new R&D facility in Hometown, PA. (Photo: Business Wire) The state-of-the-art R&D laboratory is dedicated to new materials used in the manufacture of semiconductors. Scientists in the facility will synthesize and purify new molecules down to parts per billion impurity levels and below using the latest technologies available in the industry. The researchers can assess the applications f